The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

July 27, 2021

Study Completion Date

July 27, 2021

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Ga-68 PSMA ligand

For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.

Trial Locations (1)

333

Chang Gung Memorial Hospital ,Linkou, Taoyuan

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03977610 - The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | Biotech Hunter | Biotech Hunter